Ocular Therapeutix, Inc.

NASDAQ:OCUL

Biotechnology

Healthcare
$5.94 -1.17%

-$0.11 today

Market cap
$1.31B
Beta
0.90
P/E (TTM)
-7.3
EPS (TTM)
-$1.30
52W Low $6.23High $16.44

Volume 3.67M

Average 3.00M

OCUL Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Ocular Therapeutix, Inc.NASDAQ: OCUL

Operating Income · Q1 FY2026 · quarter ended Mar 2026

Operating income remains negative

Q1 FY2026 operating income was -$93.34M, compared with -$63.92M a year earlier. Trailing-twelve-month operating income was -$299.44M.

Context

  • Operating income amounted to 521.0% of revenue in FY2025, up 251.5 pp from a year earlier.
  • Operating income grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether operating income reaches the consensus estimate from 9 analysts of -$285.76M (-5.8%) for the fiscal year ending Dec 2026, a step up from the -57.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$93.34M-33.8% QoQ
Last fiscal yearDec 2025
-$270.02M-57.2% YoY
LTMMar 2026
-$299.44M-46.7% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-46.0%-27.7%+18.3 pp
1 year-57.2%-5.8%+51.4 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

USD · from the income statement

Latest · FY2025
(270.02M) USD
Year-over-year change
-57.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How OCUL compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -46.7% is the 9th highest of 10, against a peer median of +16.8%.
  • Operating income amounts to 575.4% of revenue for OCUL, versus a peer median of 748.5%.
OCUL Competitors
Operating Income for OCUL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BLCOBausch + Lomb CorporationLTM Jun 2026$380M USD+375.0%-3.2%7.1%
HROWHarrow Health, Inc.LTM Mar 2026$28.12M USD+522.3%+172.0%10.5%
STAASTAAR Surgical CompanyLTM Apr 2026-$5.01M USD+92.6%—1.7%
SGPSpyGlass Pharma, Inc. Common StockFY2025-$41.45M USD———
OTLKOutlook Therapeutics, Inc.LTM Mar 2026-$60.57M USD+20.8%—18182.8%
OCGNOcugen, Inc.LTM Mar 2026-$66.25M USD-16.1%—1483.9%
GKOSGlaukos CorporationLTM Jun 2026-$80.49M USD+16.8%—13.1%
OCSOculis Holding AGLTM Mar 2026-CHF 84.37M CHF-8.4%—16741.0%
KODKodiak Sciences Inc.LTM Sep 2026-$251.17M USD-12.6%——
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026-$281.82M USD-74.6%—3700.9%
OCULOcular Therapeutix, Inc.LTM Mar 2026-$299.44M USD-46.7%—575.4%
Peer median (excluding OCUL) —+16.8%+84.4%748.5%

Competitors are the stored peer set for OCUL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue43.52M51.49M58.44M63.72M51.82M
Cost of Revenue4.41M4.54M5.28M5.63M6.57M
Gross Profit39.12M46.95M53.16M58.1M45.25M
Gross Margin89.9%91.2%91.0%91.2%87.3%
Research & Development50.08M53.46M61.06M127.64M197.1M
Selling, General & Admin67.07M72.15M74.49M102.24M118.3M
Operating Expenses117.15M125.61M135.54M229.88M315.39M
Depreciation & Amortization2.42M2.11M2.98M3.79M4.32M
EBITDA2.54M(61.91M)(66.42M)(176.14M)(249.78M)
EBITDA Margin5.8%-120.2%-113.6%-276.4%-482.0%
Operating Income(78.04M)(78.65M)(82.38M)(171.78M)(270.02M)
Operating Margin-179.3%-152.7%-141.0%-269.6%-521.0%
Interest Income33K798K3.98M20.28M18.36M
Interest Expense6.67M7.02M11.34M13.58M11.84M
Other Income / Expenses71.48M7.62M1.65M(21.73M)4.08M
Income Before Tax(6.55M)(71.04M)(80.74M)(193.51M)(265.94M)
Pre-Tax Margin-15.1%-138.0%-138.1%-303.7%-513.2%
Income Tax Expense00000
Net Income(6.55M)(71.04M)(80.74M)(193.51M)(265.94M)
Net Margin-15.1%-138.0%-138.1%-303.7%-513.2%
EPS (Basic)(1.05)(1.04)(1.09)(1.22)(1.42)
EPS (Diluted)(0.98)(0.97)(1.02)(1.22)(1.42)
Weighted Avg Shares76.39M76.88M79.83M158.27M187.24M
Weighted Avg Shares (Diluted)82.16M82.64M85.6M158.27M187.24M

Ocular Therapeutix, Inc.

NASDAQ:OCUL

Intrinsic Alpha fair value

Locked

Current Price

$5.94

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.